Vilobelimab（Cat No.:I042134）is a monoclonal antibody designed to inhibit the chemokine receptor CXCR4, which plays a key role in immune cell migration and inflammatory processes. It is being investigated for its potential in treating various diseases, particularly autoimmune conditions like systemic lupus erythematosus (SLE) and other chronic inflammatory diseases. By targeting CXCR4, Vilobelimab may reduce the activation of immune cells involved in inflammation, helping to manage disease symptoms and potentially improve patient outcomes. Clinical trials are ongoing to assess its safety and efficacy in these conditions.
